Physician profile
Ryan C Wanamaker
NPI 1326090358
$11,473.82
in general payments reported to CMS, 2019-2025
38 companies · $2,080 in 2025
The $2,080 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $834 · 2021: $1,143 · 2022: $2,026 · 2023: $2,227 · 2024: $1,814 · 2025: $2,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,121.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,905.44 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,851.36 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $941.16 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $859.70 | 2019-2025 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $561.48 | 2019-2025 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $357.22 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $306.89 | 2019-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $223.62 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $199.10 | 2020-2023 | |
| Redhill Biopharma INC. | $196.56 | 2020-2022 | |
| Qol Medical, LLC | $185.20 | 2023-2025 | Sucraid |
| Pfizer INC. | $182.77 | 2019-2025 | |
| Genzyme Corporation | $170.18 | 2023-2025 | |
| Celgene Corporation | $155.50 | 2021-2023 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $134.62 | 2024-2025 | Iqirvo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $127.02 | 2019-2025 | |
| Allergan, INC. | $125.27 | 2019-2020 | |
| Madrigal Pharmaceuticals | $115.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $104.81 | 2019-2025 | Rebyota |
| Ardelyx, INC. | $99.14 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $92.31 | 2024-2025 | Voquezna |
| Organon LLC | $85.12 | 2023-2025 | Hadlima, Renflexis |
| Amgen INC. | $52.15 | 2020-2023 | Amjevita, Avsola |
| Enterra Medical, INC. | $51.63 | 2025 | |
| Endogastric Solutions, INC | $49.09 | 2022 | |
| Novo Nordisk INC | $47.05 | 2025 | Wegovy |
| Lilly USA, LLC | $38.73 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $36.82 | 2019 | |
| Shionogi INC | $35.80 | 2019 | |
| Daiichi Sankyo INC. | $34.64 | 2019 | |
| Shire North American Group INC | $28.30 | 2019 | |
| Fresenius Kabi USA, LLC | $21.20 | 2023 | |
| Aimmune Therapeutics, INC. | $20.76 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $20.22 | 2024 | Givlaari |
| Ucb, INC. | $17.33 | 2019 | |
| Boston Scientific Corporation | $15.13 | 2021 | |
| Biocon Biologics INC | $13.60 | 2025 | Yesintek |
| Vbi Vaccine (Delaware) INC. | $11.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wanamaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.